Talquetamab Regimens Boost Survival in Multiple Myeloma

(MedPage Today) -- Talquetamab (Talvey) plus daratumumab (Darzalex) with or without pomalidomide (Pomalyst) significantly improved survival outcomes over an active regimen for relapsed or refractory multiple myeloma, a phase III trial showed....